Genius™ Digital Diagnostics System
First and only FDA cleared digital cytology system.
Empower Your Genius With Ours
The Genius Digital Diagnostics System is the first and only FDA cleared digital cytology system – combining a new artificial intelligence (AI) with advanced volumetric imaging technology to help cytologists and pathologists identify pre-cancerous lesions and cervical cancer cells.
Clinical Benefits
Screening for cervical cancer using Genius Digital Diagnostics provides more sensitive disease detection than manual and image-guided review.1
Streamlined Efficiency
Digital imaging and AI-guided review significantly streamlines laboratory workflows, supporting staff and reducing costs.
Innovation
Genius Digital Diagnostics offers cytologists and pathologists innovative technology that supports the future of cytology and co-testing as the most sensitive cervical cancer screening strategy.2-5
Make a Greater Impact on Cervical Cancer
7.5%
increase in HSIL+ sensitivity vs. manual review1
3.6%
increase in HSIL+ sensitivity vs. ThinPrep® Imaging System review1
Video Resources
1. Genius Digital Diagnostics System with Genius Cervical AI. US Instructions for Use AW-23890-001. Hologic, Inc.; 2024. 2. Austin RM, et al. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV co-testing. Am J Clin Pathol.2018;150(5):385-392. doi: 10.1093/ajcp/aqy114 (Study included the ThinPrep® Pap test, ThinPrep imaging, digene HPV, Cervista HPV and Aptima HPV). 3. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/ cncy.21544 (Study included ThinPrep, SurePath and Hybrid Capture 2 assay). 4. Kaufman H, et al. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074 (Study included ThinPrep Pap test, ThinPrep imaging, SurePath Pap test, SurePath imaging, Aptima HPV assay and Hybrid Capture 2 HPV assay). 5. Zhou H, et al. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. Cancer Cytopathol. 2016 May;124(5):317-23. doi: 10.1002/cncy.21687. (Study included Cobas HPV, SurePath and ThinPrep).
